OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced the appointment of Steve Forte to its Board of Directors. The appointment of Mr. Forte, who will serve on the Board's Audit Committee, increases the size of the Board to seven members. Most recently, he served as Chief Financial Officer at Clementia Pharmaceuticals Inc. (CMTA), which was acquired by Ispen S.A. for approximately US$1.3 billion in April 2019.